Impact of direct-acting antiviral therapy in Egyptian patients with chronic hepatitis C and liver cirrhosis

SAFETY AND EFFICACY OF DIRECTLY ACTING ANTIVIRAL DRUGS IN TREATMENT OF CHRONIC HCV EGYPTIAN PATIENTS

Safety and Efficacy of Direct Acting Antivirals (Sofosbuvir & Daclatasvir) in treatment of Chronic HCV in HIV-HCV Co-Infected Egyptian Patients

Efficacy and Safety of Daclatasvir and Sofosbuvir in Egyptian Patients with Chronic Hepatitis C Genotype 4 and Cirrhosis

Effect of Treatment With Direct Acting Antivirals on Glucose and Lipid Metabolism in Egyptian Patients With Chronic Hepatitis C

Outcomes of direct acting antiviral therapy for treatment of HCV infection in patients with decompensated liver cirrhosis

Evaluation of Sofosbuvir plus Ribavirinin Treatment of Cirrhotic Hepatitis C Patients: An Egyptian Study

Efficacy, Safety and Relapse of Sofosbuvir in Combination with Daclatasvir, Ledipasvir and Simeprevir for Treatment of Hepatitis C Virus in Egypt

The Real-World Safety and Efficacy of Directly Acting Antiviral Therapy for the Treatment of Patients with Hepatitis C Infection and Decompensated Cirrhosis

Efficacy of Sofosbuvir plus Daclatasvir in Treatment of Chronic HCV Infection in Egyptian Patients: A Prospective Cohort Study